Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients wit

Small-cap companies are accustomed to living in the shadow of mega-cap tech firms, but there are sig

Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report) has earned a consensus recommendation of "B

Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report)'s stock price shot up 4.5% on Monday. The c

HC Wainwright & Co. analyst Ananda Ghosh reiterates Maze Therapeutics (NASDAQ:MAZE) with a Bu

Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report)'s share price gapped up prior to trading on

Citigroup analyst Eric Joseph initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy ra

U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securit

Wedbush analyst Laura Chico reiterates Maze Therapeutics (NASDAQ:MAZE) with a Outperform and main

BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains

U.S. stocks rose, led by On Holding's 13% surge after strong guidance and a $1B buyback; Viking

Chief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026. The tra

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcri

Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market

Frazier Life Sciences Management L.P. boosted its stake in Maze Therapeutics, Inc. (NASDAQ: MAZE) by

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZ

BlackRock Inc. purchased a new position in Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefin

Bank of America Corp DE increased its holdings in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 961.3% d

Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829

ARCH Venture Management LLC bought a new position in shares of Maze Therapeutics, Inc. (NASDAQ: MAZE

Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze's Board of Directors,

BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.76) per share which missed the anal

Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026

The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). Wh

This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale,

Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 20

SOUTH SAN FRANCISCO, Calif. , May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.45) per share which beat the analys

Truist Securities analyst Danielle Brill maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and

JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and rai

The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp

US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur

BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains

Maze Therapeutics stock drops despite Phase 2 data showing uACR reductions in APOL1 kidney disease;

HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy

 – At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients,

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.65) per share which beat the analys

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S

Truist Securities analyst Danielle Brill initiates coverage on Maze Therapeutics (NASDAQ:MAZE) wi

Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raise

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1

Mizuho analyst Salim Syed initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Outperform

BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains

Guggenheim analyst Debjit Chattopadhyay maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and